^
Association details:
| Biomarker: | EGFR T790M negative |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Tagrisso (osimertinib) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC
Excerpt:
...Cohort A：EGFR T790M negative, MET amplification,(...
Trial ID:
Source:
Title:
Patient-Initiated a Phase II study (WJOG12819L) to Assess the Efficacy of Osimertinib in Patients with EGFR Mutated T790M-Negative NSCLC
Published date:
08/08/2023
Excerpt:
From August 2020 to February 2021, 55 patients from 15 institutions were enrolled in the study. The overall response for primary analysis was achieved in 16 patients (29.1%; 95% CI, 17.6-42.9), which exceeded the threshold response rate necessary for analysis. Stable disease was found in 16 patients (29.1%), and progressive disease, in 18 (32.7%). The median length of progression-free survival (PFS) was 4.07 months (95% CI 2.10-4.30), and the rate of 12-month PFS was 17.3%...Osimertinib demonstrated modest antitumor activity against progressive EGFR T790M-negative disease.
